Drug Resistance Updates
Volume 12, Issue 6 , Pages 153-156 , December 2009

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

  • Yvette Drew
    • ,
  • Ruth Plummer

      Affiliations

    • Corresponding Author InformationCorresponding author at: Northern Institute for Cancer Research, Newcastle University, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. Tel.: +44 191 2464300; fax: +44 191 2464301.

Received 14 October 2009 ,Accepted 21 October 2009.

References 

  1. Audeh MW, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. 2009;27(15S):5500;(Abstract)
  2. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, et al. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009;27:756–763
  3. Beneke S, Diefenbach J, Burkle A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int. J. Cancer. 2004;111:813–818
  4. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res. 2002;511:145–178
  5. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle. 2008;7:1353–1359
  6. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917
  7. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan Koch SS, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 2004;96:56–67
  8. Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J. Med. Chem. 2002;45:4961–4974
  9. Chambon P, Weil J, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid sythesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 1963;11:39–43
  10. Curtin NJ. PARP inhibitors for cancer therapy. Exp. Rev. Mol. Med. 2005;7:1–20
  11. de Murcia G, Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 1994;19:172–176
  12. Edwards S, Brough R, Lord C, Natrajan R, Vatcheva R, Levine D, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111–1115
  13. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PWB, et al. Selective inhibition of BCRA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Cancer Res. 2008;14:3916–3925
  14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921
  15. Fong PC, Boss DS, Yap T, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009;361:123–134
  16. Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 2005;111:127–148
  17. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol. Res. 2005;52:109–118
  18. Heinen CD, Schmutte C, Fishel R. DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Cancer Biol. Ther. 2002;1:477–485
  19. Hoeijmakers JH. Genone maintenance mechanisms for preventing cancer. Nature. 2001;411:360–374
  20. Kopetz S, Mita M, Mok I, Sankhala K, Moseley J, Sherman B, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J. Clin. Oncol. 2008;26:3577
  21. Kummar S, Ji J, Zhang Y, Simmons D, Kinders R, Gutierrez ME, et al. A pPase I combination study of Abt-888 and topotecan hydrochloride in adults with refractory solid tumors and lymphomas. Ann. Oncol. 2009;20:42
  22. Mahany J, Lewis N, Heath E, LoRusso P, Mita M, Rodon J, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J. Clin. Oncol. 2008;26:3579
  23. Moll U, Lau R, Sypes MA, Gupta MM, Anderson CW. DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene. 1999;18:3114–3126
  24. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J. Clin. Oncol. 2009;27:3
  25. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 2008;14:7917–7923
  26. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J. Clin. Oncol. 2006;24:8013
  27. Rajan A, Carter CA, Gutierrez M, Kummar S, Yancey MA, Ji JP, et al. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin plus gemcitabine in adults with solid tumors. J. Thorac. Oncol. 2009;4:S598–S599
  28. Rajan A, Gutierrez M, Kummar S, Yancey M, Ji J, Zhang Y, et al. A phase I combination study of AZD2281 and cisplatin plus gemcitabine in adults with solid tumors. Ann. Oncol. 2009;20:42–43
  29. Sakai W, Swisher E, Karlan B, Agarwal M, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116–1120
  30. Sakai W, Swisher EM, Jacquemont C, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009;69:6381–6386
  31. Shahzad MMK, Lopez-Berenstein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resist. Updat. 2009;12:148–152
  32. Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G, et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum. Pathol. 2005;36:724–731
  33. Stordal B, Davey R. A systematic review of genes involved in the inverse relationship between cisplatin and paclitaxel chemotherapy: roel of BRCA1. Curr. Cancer Drug Targets. 2009;9:354–365
  34. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Res. 2002;45:73–85
  35. Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol. 2009;27(18s):CRA501
  36. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 2003;63:6008–6015
  37. Wharton SB, McNelis U, Bell HS, Whittle IR. Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model. Neuropathol. Appl. Neurobiol. 2000;26:528–535

PII: S1368-7646(09)00063-6

doi: 10.1016/j.drup.2009.10.001

Drug Resistance Updates
Volume 12, Issue 6 , Pages 153-156 , December 2009

Article Tools